Jubilant Life Sciences, a key supplier of radiology medicines in the U.S., is being investigated by U.S. antitrust regulators over its business practices, according to a recent regulatory filing.

The probe began in 2017 after several nuclear pharmacies expressed concerns that a Jubilant subsidiary forced them into unfavorable contracts. And this past February, regulators sought information from Jubilant about its acquisition of a chain of more than 59 pharmacies around the U.S., which independent operators complained would pose an unfair competitive threat.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Upon re-reading the linked story I noticed what I had failed to observe here: “During a May 2014 conference call, however, Rajagopal Sankaraiah, the Jubilant chief financial officer, told investors these were “not just mere price hikes.” This has been 4 full years in the making – and they 100% of the market even then. How did that happen without any authority observing the change?

    • There have been several alternate solutions that radiopharmacies across the country have tried to put into place and Jubilant has gone as far as contacting the FDA and threatening lawsuits against several radiopharmacies due to possible negative impacts on their own market share. The quote about being more than just price hikes – being in an enviable place in the market – is no excuse for 1800% price hikes! It’s more ammunition for anti-trust investigations!! It literally defines the problem for this particular situation.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy